Source – The Science Behind d-Lanelate® Studies 1999 – 2014. East Park™ Research
To evaluate the efficacy of East Park d-Lenolate in the control of symptoms of Candida
Candidates for the study were obtained through advertising. Subjects identified themselves as
having been treated for several years for yeast infections without success.
A double-blind, randomized placebo control study was conducted in 30 subjects for 60 days.
Basal metabolic panels, complete blood counts, and Somatomedin-C levels of each subject were
recorded at the beginning and completion of the study. A yeast infection questionnaire was filled
out by each participant at the beginning and conclusion of the study.
Subjects took 6 capsules per day of either the d-Lenolate or the placebo. There were no
modifications to the diet or exercise programs of the participants during the study period, and no
additional nutritional supplements were prescribed.
Our study was conducted from January through June of 1999.
Virtually all of the subjects had normal blood count and basal metabolic panels. The mean score
at baseline was 250. Within 60 days of taking the d-Lenolate, symptoms were reduced by
greater than 50%. The reduction of symptoms in the placebo group was significantly less than in
the group taking the d-Lenolate.
East Park d-Lenolate will reduce the symptoms of chronic yeast infections by greater than 50%
within 60 days of its use with no apparent side effects. Continued use may be warranted to
enhance an ongoing treatment protocol.